The pituitary gland is a critical organ that is necessary for many physiological processes, including growth, reproduction, and stress response. The secretion of pituitary hormones from specific cell types regulates these essential processes. Pituitary hormone cell types arise from a common pool of pituitary progenitors, and mutations that disrupt the formation and differentiation of pituitary progenitors result in hypopituitarism. Canonical WNT signaling through CTNNB1 (b-catenin) is known to regulate the formation of the POU1F1 lineage of pituitary cell types. When b-catenin is deleted during the initial formation of the pituitary progenitors, Pou1f1 is not transcribed, which leads to the loss of the POU1F1 lineage. However, when b-catenin is deleted after lineage specification, there is no observable effect. Similarly, the generation of a b-catenin gain-of-function allele in early pituitary progenitors or stem cells results in the formation of craniopharyngiomas, whereas stimulating b-catenin in differentiated cell types has no effect. PROP1 is a pituitary-specific transcription factor, and the peak of PROP1 expression coincides with a critical time point in pituitary organogenesis-that is, after pituitary progenitor formation but before lineage specification. We used a Prop1-cre to conduct both loss-and gain-of-function studies on b-catenin during this critical time point. Our results demonstrate that pituitary progenitors remain sensitive to both loss and gain of b-catenin at this time point, and that either manipulation results in hypopituitarism. (Endocrinology 159: 3287-3305, 2018) 
C ombined pituitary hormone deficiency (CPHD) is defined as the combination of GH deficiency with a deficiency of at least one additional hormone. Mutations in the pituitary-specific transcription factors PROP1 and POU1F1 (PIT1) are the most common causes of human CPHD (1) . In mice, POU1F1 is required for transcription of three pituitary hormones: GH, TSHb, and prolactin (PRL). Therefore, mutations in Pou1f1 result in the loss of three hormone cell types: somatotropes, which secrete GH; thyrotropes, which secrete TSH; and lactotropes, which secrete PRL (2) . PROP1 promotes the early transcription of Pou1f1; therefore, mutations in Prop1 also result in deficiencies in these three cell types (3) . Prop1 is expressed in the common pool of pituitary progenitor cells in Rathke's pouch, the precursor of the pituitary anterior lobe (4) . These pituitary progenitors will produce the hormone cell types of the POU1F1 lineage as well as corticotropes, which secrete ACTH, melanotropes, which secrete MSH, and gonadotropes, which secrete LH and FSH. PROP1 regulates the epithelialto-mesenchymal transition (EMT)-like transition necessary to release the pituitary progenitors from the proliferative zone in the periluminal region of Rathke's pouch and into the forming anterior lobe (5) . In addition to deficiency in the POU1F1 lineage hormones, people with PROP1 mutations are also deficient in gonadotropins and can develop ACTH deficiency (6) .
PROP1 and POU1F1 are just two of a hierarchy of transcription factors necessary for the differentiation of pituitary progenitors into the anterior lobe hormone cell types. In mice, this transcriptional hierarchy begins at embryonic day of development (e)9.5 with transcription factors that are necessary for establishing the pituitary progenitors in Rathke's pouch, including SOX2, PITX1, PITX2, LHX3, LHX4, HESX1, and ISL1 (7) . Between e9.5 and e11.5, the pituitary progenitors proliferate around the lumen of Rathke's pouch. Between e11.5 and e13.5, the pituitary progenitors begin exiting the cell cycle, during the peak of PROP1 expression (8, 9) . On the rostral and ventral side of Rathke's pouch, the pituitary progenitors perform an EMT-like transition and enter the newly forming anterior lobe (5) . Beginning at e14.5, these typically postmitotic cells begin to express lineage-specific intermediate markers of differentiation, including POU1F1 in somatotropes, thyrotropes, and lactotropes; TBX19 (TPIT) in corticotropes; and NR5A1 (SF1) in gonadotropes (2, 10, 11) . Mutations in any of these transcription factors will cause loss of multiple pituitary hormones (CPHD) or individual pituitary hormones (isolated hormone deficiency), depending on the function of the transcription factor within the transcriptional hierarchy (7) .
Several signaling pathways, including BMP, FGF, NOTCH, and WNT, are known to stimulate various members of the transcriptional hierarchy (7) . BMP signaling can induce Isl1, and FGF signaling can induce Lhx3 expression in the pituitary progenitors (12) . NOTCH signaling regulates Prop1 expression through an RBPJ binding domain located in the first intron (13) . Wnt4 2/2 mice have a decrease in Pou1f1 expression and reduced somatotropes and thyrotropes (14, 15) . WNT signaling is complex and is mediated by canonical and multiple noncanonical pathways (16, 17) . Canonical WNT signaling is dependent on the nuclear accumulation of CTNNB1 (b-catenin), whereas noncanonical pathways are independent of b-catenin. Canonical WNT signaling likely mediates the WNT4 transcriptional regulation of Pou1f1. A b-catenin conditional lossof-function experiment using the Pitx1-cre to delete b-catenin from the pituitary progenitors at e9.5 demonstrated that b-catenin is required for Pou1f1 transcription (18) . b-catenin forms a complex with PROP1 to initiate the early transcription of Pou1f1. Deletion of b-catenin using a Pou1f1-cre did not result in a pituitary phenotype, demonstrating that canonical WNT signaling is not necessary for pituitary cell specification after the pituitary cell lineages have begun to express intermediate markers of differentiation (18) . Gain-of-function experiments using an inducible allele of b-catenin, which results in a degradation-resistant protein, demonstrate that canonical WNT signaling promotes pituitary stem cell formation (19) . The production of the degradation-resistant b-catenin in pituitary progenitors at e9.5 using the Hesx1-cre causes the formation of adamantinomatous craniopharyngiomas (ACPs) (20) . ACPs are benign tumors that do not express pituitary hormones, but result in high morbidity, resulting from mass effects of the tumors (21) . Stimulating canonical WNT signaling in pituitary progenitors also results in an increase in the pituitary stem cell population. When the degradation-resistant b-catenin is generated using the Pou1f1-cre, GH-cre, or PRL-cre, no altered phenotype is observed (20) . Coupled with the b-catenin loss-of-function results, these experiments demonstrate that canonical WNT signaling affects pituitary progenitor formation and cell specification in a critical period between e9.5 and e14.5. The Prop1-cre is active beginning at e11.5, following pituitary progenitor formation and before commitment to the pituitary hormone lineages (4) . Utilizing the Prop1-cre in combination with both b-catenin conditional loss-of-function and gain-of-function alleles, we manipulated canonical WNT signaling to determine whether pituitary progenitor cells are sensitive or refractory to canonical WNT signaling at this critical time point when pituitary progenitors exit the cell cycle, undergo an EMT-like transition, and form the nascent anterior lobe.
Methods

Mice
The Institutional Committee on the Use and Care of Animals for the University of South Carolina approved all experiments using mice. The Ctnnb1 tm2Kem (b-cat fx/fx ) and Gt(ROSA)26
Sortm4(ACTB-tdTomato,-EGFP)Luo (Rosa mTmG ) mice were obtained from The Jackson Laboratory (Bar Harbor, ME) (22) . Ctnnb1 tm1Mmt (b-cat GOF ) mice were obtained from Mark Taketo at Kyoto University via Santhakumar Manicassamy of Augusta University (19) . Prop1-cre mice were generated at the University of Michigan and are available from the Mutant Mouse Resource and Research Center at the University of North Carolina at Chapel Hill (4). Mice were fed without restriction and housed in specific pathogen-free conditions with automatic watering. Genotyping of mice was performed as previously reported (4, 19, 22) . The observation of a copulation plug was used to initiate the timing of embryonic development, with noon on the day the copulation was observed being defined as e0.5. Sexual dimorphism of the pituitary gland is not observed until after birth (23) . Therefore, tissues were chosen for experiments without regard for sex. All experiments were conducted using at least four mutant embryos.
Histology, immunostaining, and RNAscope
Embryos at appropriate developmental time points were collected and fixed overnight in 4% paraformaldehyde in PBS at 4°C. The fixative was removed and the embryos were washed in PBS, dehydrated into 100% ethanol, permeabilized with methyl salicylate, and embedded in paraffin (24) . Sixmicrometer sections were generated, and selected sections were chosen for histology and stained with hematoxylin and eosin (H&E) (24) .
Immunostaining information is included in Table 1 , including antibody sources and dilutions. All immunostaining experiments, except for pituitary hormone immunostaining, were boiled in 10 mM citric acid (pH 6.0) for 10 minutes to retrieve epitopes. Experiments utilizing horseradish peroxidase (HRP) for signal detection were incubated in 50% methanol and 1.5% hydrogen peroxide for 20 minutes at room temperature to inactivate endogenous peroxidases. Immunostaining experiments performed with mouse primary antibodies used blocking reagents from the M.O.M. kit as recommended by the manufacturer (Vector Laboratories), whereas primary antibodies from other species used the blocking reagent from tyramide signal amplification (TSA) kit no. 22 dissolved in PBS (Thermo Fisher Scientific). Primary antibodies were incubated overnight at 4°C in the TSA blocking reagent, followed by species-specific secondary antibodies diluted 1:100 in TSA block and incubated for 30 minutes at room temperature. For biotin-conjugated secondary antibodies, streptavidin conjugates (HRP, Alexa Fluor 488, or Alexa Fluor 594) were diluted 1:100 in TSA block and incubated for 30 minutes at room temperature (Thermo Fisher Scientific). Streptavidin-HRP conjugates were either followed by SigmaFast 3,3 0 -diaminobenzidine (DAB) staining (Sigma-Aldrich) or TSA with Alexa Fluor 488 (TSA kit no. 22, Thermo Fisher Scientific) for 3 minutes. Fluorescent detection methods were counterstained with 300 nM 4 0 ,6-diamidino-2-phenylindole (DAPI) for 5 minutes before mounting in fluorescence mounting media, whereas DAB detection was counterstained with 0.5% methyl green in 0. (31, 53) .
In situ detection of b-catenin mRNA using the RNAscope 2.5 HD reagent kit-BROWN (Advanced Cell Diagnostics) was performed according to the manufacturer's recommendations, as previously reported, on tissue sections, cut at 6-mm thickness (33) . Both positive and negative control probes supplied by the manufacturer were tested on all tissues used for the RNAscope. Tissues were counterstained with a 50% hematoxylin solution.
Quantification experiments
To determine the proportion of total cells expressing POU1F1 or SF1 at e14.5, the total number of POU1F1-or SF1-positive cells in the forming anterior lobe was counted in images of midsagittal sections from four normal control embryos and four Prop1-cre;b-cat fx/fx mutant embryos using the cell counter feature in ImageJ. The total number of DAPI-stained nuclei in the forming anterior lobe was also counted for each image to determine the total number of cells. Dividing the total number of POU1F1-or SF1-positive cells by the number of DAPI-stained nuclei produced the proportion of POU1F1-or SF1-positive cells for each embryo. The proportion of TBX19-positive cells was similarly determined except that the proportion of TBX19-positive cells and DAPI nuclei was also determined in the intermediate lobe to differentiate between anterior lobe corticotropes and intermediate lobe melanotropes. The proportion of hormone-positive cells for four normal control and four Prop1-cre;b-cat fx/fx mutant embryos was determined using images of coronal sections at e18.5 as above.
The periluminal epithelium of Rathke's pouch is characterized by columnar cells in a pseudostratified epithelium. These cells are morphologically distinct from the epithelioid cells of the pituitary parenchyma in the anterior lobe. This morphological distinction was used to select a region of interest containing the periluminal epithelium on images of H&E-stained normal control and Prop1-cre;b-cat GOF mutant embryos; the area of the region of interest was determined using ImageJ. For each of four normal control and four Prop1-cre;b-cat GOF mutant embryos, five sections distributed across the left-to-right axis of the pituitary gland were selected and the area of periluminal epithelium was determined for each section along with an overall average area of periluminal epithelium for each embryo.
To determine differences in expression of SOX9 at e14.5 in high and low b-catenin expression regions of Prop1-cre; b-cat GOF mutant embryos, b-catenin and SOX9 doubleimmunostained images were analyzed in ImageJ. Regions of high b-catenin expression were used to determine regions of interest, and within these regions, the total number of SOX9-positive cells and the total number of DAPI-stained nuclei were used to generate a proportion of SOX9-positive cells. Periluminal epithelial cells with low b-catenin expression were used to determine regions of interest with low b-catenin expression, and the proportion of SOX9-positive cells was also determined within these regions of interest. Single images from four individual Prop1-cre;b-cat GOF mutant embryos were analyzed. To determine differences in CCND2 expression at e16.5 in normal control intermediate lobe and regions with high and low b-catenin expression in Prop1-cre;b-cat GOF mutant embryos, the proportion of CCND2-positive cells was determined as above in each region. For normal control embryos, single images from four embryos were analyzed. For Prop1-cre;b-cat GOF mutant embryos, three images from each of four mutant embryos were analyzed. In Prop1-cre;b-cat GOF mutant embryos, the regions of high b-catenin expression were separated into large clusters, which had an average of 209 cells and a range of 59 to 424 cells, and small clusters, which had an average of 14 cells and a range of 3 to 57 cells.
Results
Pituitary-specific b -catenin loss of function
Canonical WNT signaling is dependent on the nuclear accumulation of b-catenin. We sought to inhibit canonical WNT signaling in pituitary progenitors using a conditional null approach. The Ctnnb1 tm2Kem (b-cat fx ) allele has loxP sites flanking exons 2 through 6 and results in a null allele in the presence of cre recombinase (22) . The Prop1-cre mediates cre recombination beginning at e11.5 in the pituitary progenitors of Rathke's pouch (4) . We crossed Prop1-cre;b-cat fx/+ with b-cat fx/fx mice to produce Prop1-cre;b-cat fx/fx embryos with b-catenin deleted in the pituitary progenitors as well as normal control embryos, which were either Prop1-crenegative or were b-cat fx/+ . In addition to functioning in the canonical WNT signaling pathway, b-catenin is also present at adherens junctions and can persist at the membrane for many hours following cre-mediated deletion (54) . We performed immunostaining for b-catenin to determine when the protein was deleted from Rathke's pouch ( Fig. 1) . At e12.5, e14.5, and e18.5, b-catenin is detectable throughout the developing pituitary gland of normal control embryos, primarily at the cell membrane . We also assessed b-catenin deletion using RNAscope, which is a highly sensitive RNA in situ hybridization technique that has been previously used in the pituitary gland (33, 55) . At e12.5 in normal control embryos, b-catenin mRNA is readily detectable in the epithelium of Rathke's pouch; however, in the forming anterior lobe, b-catenin transcription is sharply reduced [ Fig Despite the continued presence of b-catenin protein at the plasma membrane, deletion of the b-cat fx/fx locus can impair canonical WNT signaling (54) . LEF1 is a transcription factor that partners with b-catenin to mediate canonical WNT signaling. Lef1 is also a transcriptional target of canonical WNT signaling and is used as a marker of canonical WNT signaling activity (57) . In normal control embryos, LEF1 expression is seen throughout the anterior lobe at e14.5 [ Fig. 1(m) ]. In Prop1-cre;b-cat fx/fx mutant embryos, LEF1 is not observed in the anterior lobe at e14.5 [ Fig. 1(n) ]. LEF1 expression is maintained in the anterior lobe at e18.5 in normal control embryos, but is not observed in Prop1-cre;b-cat fx/fx mutant embryos [ Fig. 1 (o) and 1(p)]. These results demonstrate that canonical WNT signaling is compromised in these Prop1-cre;b-cat fx/fx mutant embryos as a result of b-catenin deletion.
POU1F1 is expressed in future somatotropes, thyrotropes, and lactotropes at e14.5, whereas TBX19 is expressed in corticotropes, and SF1 is expressed in gonadotropes [ Fig. 2 (a)-2(c)] (10, 11, 58, 59) . Pou1f1 is a direct transcriptional target of b-catenin (18); in Prop1-cre;b-cat fx/fx mutant embryos, POU1F1 expression is almost absent from the anterior lobe, whereas TBX19 is increased, and SF1 appears unchanged [ Fig.  2 
We determined the proportion of total cells for each intermediate marker of differentiation (POU1F1, SF1, and TBX19) at e14.5 [ Fig. 2(g) ]. For POU1F1 and SF1, only cells in the anterior lobe were counted, whereas for TBX19 the proportion in the anterior lobe was determined separately from those in the intermediate lobe to separate corticotropes in the anterior lobe from melanotropes in the intermediate lobe. The mean proportion of each cell type from four individuals of each genotype was compared using a two-sample t test with unequal variance. As expected from a visual inspection of the immunostained images, POU1F1 was significantly reduced in Prop1-cre;b-cat fx/fx mutant embryos compared with normal controls (P = 0.014). TBX19 expression in the anterior lobe was previously shown to increase when b-catenin was deleted in early pituitary progenitors (18) ; therefore, we expected to observe an increase in Prop1-cre;b-cat fx/fx mutant embryos compared with normal control embryos. In the anterior lobe, the mean proportion of TBX19-positive cells was significantly increased in Prop1-cre;b-cat fx/fx mutant embryos (P = 0.041), whereas in the intermediate lobe, the mean proportion of TBX19 cells was not significantly different between the two genotypes (P = 0.557). The mean proportion of SF1-positive cells was also increased in Prop1-cre;b-cat fx/fx mutant embryos compared with normal controls (P = 0.014). By e18.5, POU1F1 expression appears to have recovered, but it had not reached the expression level of normal control embryos Rosa mTmG/+ embryos and normal control littermates. We used expression of enhanced GFP (eGFP) from the recombined Rosa mTmG locus to visualize recombination in Prop1-cre-positive pituitary glands. In normal control embryos, immunostaining for GFP shows that membrane-bound eGFP is observed in all anterior lobe cells at e14.5 [ Fig. 3 (i)-3(l)], which demonstrates efficient recombination at the Rosa locus by the Prop1-cre. In Prop1-cre;b-cat fx/fx ;Rosa mTmG/+ mutant embryos, we observed small patches of eGFP-negative cells in the anterior lobe, demonstrating that in these mutant embryos, some pituitary progenitors are able to escape recombination mediated by the Prop1-cre [ Fig. 3(m)-3(p) ]. In these small eGFP-negative cells, POU1F1 is expressed. Therefore, POU1F1 expression likely results from a failure to recombine the b-catenin locus, instead of persistent protein expression following cre recombination.
Members of the LEF/TCF family of transcription factors mediate canonical WNT signaling by forming a complex with b-catenin and regulating transcription of target genes. In the pituitary gland, PROP1 and b-catenin form a complex that is necessary for the activation of POU1F1 (18, 61) . The transcriptional activation of POU1F1 by PROP1/b-catenin is inhibited by LEF1 in a transiently transfected pituitary cell line (18) . Given the negative regulation of POU1F1 by LEF1, we expected that LEF1-positive cells in the anterior lobe would not express POU1F1. We performed double immunostaining for POU1F1 and LEF1 on normal control embryos at Fig. 3(u)-3(x) ]. This result indicates that in Prop1-cre;b-cat fx/fx mutant embryos, canonical WNT signaling is activated in POU1F1 cells, and likely results from the presence of pituitary progenitor cells that did not undergo recombination at the b-catenin locus.
Pituitary-specific b-catenin gain of function
Previous studies demonstrated that stimulation of canonical WNT signaling at e9.5 or e10.5, using a b-catenin conditional gain-of-function allele (Ctnnb1 tm1Mmt or b-cat GOF ), results in pituitary dysmorphology and ACP formation (20, 62) . This is in contrast to stimulating canonical WNT signaling at e14.5 or later, which has no observed effect on pituitary function (20) . We used the Prop1-cre and the b-cat GOF allele to stimulate canonical WNT signaling beginning at e11.5. Histological examination of e16.5 Prop1-cre;b-cat GOF pituitaries compared with normal control pituitaries indicates that stimulating canonical WNT signaling at this time point also results in highly dysmorphic pituitaries, demonstrating that pituitary progenitors at e11. We determined the average area of periluminal epithelial tissue from five sagittal sections distributed across the lateral to medial axis for four normal control embryos and four Prop1-cre;b-cat GOF mutant embryos at e14.5, when the dysmorphology becomes clearly apparent. A representative region of periluminal epithelial tissue is outlined in Fig. 4 (i) and 4(j). Normal control embryos had a mean periluminal epithelial area of 27.5 6 4.6 mm 2 , whereas Prop1-cre;b-cat GOF mutant embryos had a mean periluminal epithelial area of 118. Fig. 5(o) ]. PROP1 expression in Prop1-cre;b-cat GOF mutant embryos is limited to the thin periluminal epithelium and is not expressed in the bulging areas of periluminal epithelium characterized by high b-catenin expression [ Fig. 5(p) ]. NOTCH2 is also expressed in the periluminal epithelium of e14.5 normal control embryos [ Fig. 5(q) ], and its expression is dependent on PROP1 (40) . In Prop1-cre;b-cat GOF mutant embryos, NOTCH2 is also expressed in the thin periluminal epithelium and is not expressed in the bulging periluminal regions [ Fig. 5(r) ]. We hypothesized that high levels of b-catenin inhibit the expression of PROP1, limiting its expression to regions of lower b-catenin expression.
To confirm this hypothesis, we modified our immunostaining for b-catenin to decrease the sensitivity. Under these modified conditions, b-catenin could not be detected in normal control embryos at e14. [ Fig. 6(u) ], which was significantly different from the mean proportion of 0.602 6 0.165 in the remaining periluminal epithelium (two-sample t test assuming unequal variances, P = 0.008). These results suggest that the high b-catenin cell clusters do not have a pituitary identity, as they do not express early, intermediate, or definitive markers of pituitary cell types, with the exception of SOX9, which has sharply reduced expression.
ACPs are slow-growing tumors characterized by a low proliferative index. Using Ki67 to identify actively cycling cells, we found that e14. control and the mutant low b-catenin-expressing epithelium was not significantly different, suggesting that these two regions are equivalent [two-sample t test assuming unequal variances, P = 0.175; Fig. 7(e) ]. Comparisons between the mutant low b-catenin-expressing epithelium and both the large, high b-catenin cell clusters (two-sample t test assuming unequal variances, P = 0.0007) and small, high b-catenin cell clusters (twosample t test assuming unequal variances, P = 0.002) were significantly different, suggesting that CCND2 is upregulated in the small, high b-catenin cell clusters and downregulated in the large, high b-catenin cell clusters [ Fig. 7(e) ]. Our analysis of both Ki67 and CCND2 indicates that the large, high b-catenin cell clusters have a reduced proliferative capacity. ACP tumors from Hesx1-cre;b-cat GOF mice are characterized by the expression of CK8 and CK18, which is suggestive of an oral ectoderm identity (20) . We performed immunostaining on normal control and Prop1-cre;b-cat GOF mutant embryos with an antibody that recognizes both CK8 and CK18 at e18.5, in combination with b-catenin immunostaining to identify regions of high b-catenin expression [ Fig. 7 (f) and 7(g)]. We observed CK8/CK18 expression throughout the pituitary gland of normal control embryos, demonstrating that this epithelial marker does not discriminate between the epithelium of the intermediate lobe and the parenchyma of the anterior lobe. CK8/CK18 is expressed in Prop1-cre;b-cat GOF mutant embryos in the epithelia outside of the high b-catenin cell clusters, which is similar to the expression in normal control littermates. This pattern recapitulates the pattern observed with other pituitary markers, which are not expressed in the regions of high b-catenin expression. Sox2 creERT2 ;b-cat GOF mice also form ACP where cell foci with high b-catenin expression express signaling factors, including SHH. SHH is expressed in the embryonic oral ectoderm prior to Rathke's pouch invagination (15) . We performed double immunostaining for SHH and b-catenin at e18.5 on normal control and Prop1-cre;b-cat GOF mutant embryos
[ Fig. 7 (h) and 7(i)]. SHH is not expressed in normal control pituitaries, but it is expressed in Prop1-cre; b-cat GOF mutant embryos in regions of high b-catenin expression. Although SHH is not a definitive marker for oral ectoderm, SHH expression in the high b-catenin cell clusters is suggestive of a conversion from pituitary to oral ectoderm.
Discussion
The differentiation of pituitary anterior and intermediate lobe hormone cell types is characterized by a series of discrete stages. The first stage is the induction of pituitary progenitors or stem cells in Rathke's pouch between e9.5 and e10.5 and is characterized by the expression of early pituitary transcription factors, including LHX3, ISL1, HESX1, and SOX2. The second stage begins at e11.5 when Rathke's pouch has closed and separated from the oral ectoderm. During this second stage, pituitary progenitors begin to exit the cell cycle and undergo an EMTlike transition from the epithelia of Rathke's pouch to form the parenchyma of the anterior lobe. Because the anterior lobe parenchyma is not a true mesenchyme, we refer to this transition as an epithelial-to-parenchymal transition (EPT). PROP1 is expressed during this second stage and is required for the EPT that will form the anterior lobe (5). The third stage begins when lineage-specific transcription factors-TBX19, SF1, and POU1F1-are expressed, which are necessary for the differentiation of specific cell types from the common pool of pituitary progenitors. The last stage is terminal differentiation, which is characterized by the expression of cell type-specific hormones. Canonical WNT signaling through b-catenin is critical for pituitary gland organogenesis. Previous studies have determined that b-catenin loss of function or gain of function at the pituitary progenitor induction stage can severely disrupt pituitary organogenesis, whereas b-catenin loss of function or gain of function at the differentiation stage has no effect (18, 20) . These results demonstrate that pituitary progenitors are sensitive to canonical WNT signaling before commitment to specific lineages. An open question is whether pituitary progenitors remain sensitive to canonical WNT signaling during the EPT stage, before the appearance of the lineage-specific transcription factors. The Prop1-cre enabled us to target b-catenin loss-of-function and gain-of-function studies to this critical period of pituitary development. Our results demonstrate that pituitary progenitors remain sensitive to canonical WNT signaling during pituitary EPT, suggesting that pituitary progenitors have not yet committed to specific cell lineages and remain b-catenin loss of function during EPT Our results are similar to previous studies that used the Pitx1-cre to delete b-catenin from the oral ectoderm at e9.5 prior to Rathke's pouch invagination (18) . Pitx1-cre;b-catenin fx/fx embryos do not express POU1F1, GH, PRL, or TSHb, whereas Prop1-cre;b-cat fx/fx mutant embryos have a reduced expression of POU1F1, GH, and TSHb. PROP1 and b-catenin form a transcriptional complex that promotes the early transcription of POU1F1 (18) . We have determined that POU1F1-positive cells in Prop1-cre; b-cat fx/fx mutant embryos express b-catenin. The presence of b-catenin in Prop1-cre;b-cat fx/fx cells could result from the persistence of a pool of b-catenin protein in the cell following generation of the b-catenin-null allele (54) . However, a more likely possibility is that in some Prop1-cre; b-cat fx/fx mutant cells the Prop1-cre transgene is not transcribed and the b-catenin-null allele is not generated. Regardless of the mechanism, the expression of LEF1 in the Prop1-cre; b-cat fx/fx mutant anterior lobe demonstrates that canonical WNT signaling occurs in these cells and implies that b-catenin is also available to promote POU1F1 transcription. In cell culture, LEF1 expression inhibits the transcription of a POU1F1 reporter construct, and Lef1 2/2 mice have an increase in the POU1F1 lineage (18) . Additionally, microRNA26b inhibits LEF1 expression and increases POU1F1 (66) . However, our results demonstrate that in vivo LEF1 and POU1F1 can be coexpressed in the same cell, implying that LEF1 expression does not preclude POU1F1 expression.
In normal control embryos, the Prop1-cre efficiently targets an eGFP reporter construct in the Rosa locus and generates membrane-bound eGFP in all anterior lobe cells. In Prop1-cre;b-cat fx/fx mutant embryos, some cells in the anterior lobe do not express eGFP. This result implies that these cells have differentiated without activating the Prop1-cre transgene. In support of this possibility, Ames dwarf mice, which are homozygous null for Prop1, have small patches of cells that express POU1F1 and differentiate into each of the POU1F1 lineage cell types (67) . Therefore, it is possible for some pituitary progenitors to differentiate into the POU1F1 lineage without activating Prop1. We think that in some Prop1-cre;b-cat fx/fx progenitor cells the Prop1-cre is not activated; therefore, the b-catenin-null allele is not generated and POU1F1 is transcribed in these cells. How POU1F1 is activated in the absence of PROP1 is not known, but implies an alternative compensatory mechanism for POU1F1 activation other than by a PROP1/ b-catenin complex. Similar to previous results using Pitx1-cre;b-catenin fx/fx mutant embryos (18), Prop1-cre;b-cat fx/fx mutant embryos have a significant increase in TBX19 expression. SF1 was not altered in Pitx1-cre;b-catenin fx/fx mutant embryos, whereas we found a small but significant increase in SF1 expression in Prop1-cre;b-cat fx/fx mutant embryos. The difference in SF1 expression between Pitx1-cre;b-catenin fx/fx and Prop1-cre;b-cat fx/fx mutant embryos may result from variations in small sample sizes in the two studies and may not represent a meaningful difference. However, the increase in TBX19 and, possibly, SF1 expression when POU1F1 is reduced suggests that a fate switch occurs in pituitary progenitors in the absence of canonical WNT signaling. Lineage tracing studies using Prop1-cre demonstrate that all pituitary hormone cell types arise from a common pool of PROP1-expressing pituitary progenitors (4) . Canonical WNT signaling in a subset of pituitary progenitors likely promotes the POU1F1 lineage. Pituitary hormone cell types can be generated from embryonic stem cells (68) (69) (70) . The primary hormone produced in these cultures is ACTH, which requires TBX19 expression. The percentage of GH-and POU1F1-expressing cells can be increased by adding a small molecule that stimulates canonical WNT signaling, supporting the need for canonical WNT signaling in pituitary progenitors to promote the POU1F1 lineage (70) .
How a subset of pituitary progenitors receives a canonical WNT signal in vivo to promote the POU1F1 lineage is unknown. Multiple WNT ligands are expressed in the pituitary progenitors in the luminal area of Rathke's pouch, including WNT4, WNT5A, WNT11, and WNT16 (14, 15 (71, 72) . Further studies are needed to determine the receptor and ligand pairs that are necessary for promoting canonical WNT signaling and the POU1F1 lineage. Canonical WNT signaling and b-catenin are associated with actively promoting EMT during development and cancer metastasis (73) . In the pituitary gland, loss of b-catenin does not inhibit the EPT necessary for forming the pituitary anterior lobe, as Prop1-cre;b-cat fx/fx mutant embryos have an anterior lobe that is morphologically similar to normal control embryos. This morphology is in contrast to Prop1 2/2 pituitaries, which have a dysmorphic pituitary gland, with a reduced anterior lobe and an increase in luminal epithelium (74) . Although PROP1 and b-catenin form a complex necessary for POU1F1 transcription, this complex does not appear necessary for promoting the EPT necessary for anterior lobe formation.
b-catenin gain of function during EPT Gain-of-function mutations in b-catenin in early pituitary progenitors or adult pituitary stem cells cause the formation of ACP (20, 62) . We have refined the period of sensitivity for pituitary progenitors to canonical WNT signaling by demonstrating that b-catenin gain-offunction mutations in pituitary progenitors during the EPT period of pituitary development also result in an ACP-like dysmorphology. This dysmorphology is characterized by a more than threefold increase in epithelial area within the developing pituitary gland. The large increase in epithelial area is similar to the dysmorphic pituitaries produced by generating the b-cat GOF/+ using the Sox2 creERT2 and administering tamoxifen at e10.5 (62). The Prop1-cre initiates recombination 1 day later at e11.5, and small foci of b-catenin accumulation are (73) . The inhibition of EPT in the pituitary gland as a result of the b-catenin GOF protein is unusual. PROP1 is necessary for promoting EPT through the transcription of Zeb2, Gli2, Mmp2, Mmp3, and Mmp16, while inhibiting the transcription of Cldn23 (Claudin23) and CDH1 (E-cadherin) (5). Notch2 transcription is also stimulated by PROP1, and NOTCH signaling is known to promote EMT in cancer and development (5, 75, 76) . Both PROP1 and NOTCH2 are inhibited by high levels of b-catenin; therefore, we think that the transcriptional profile necessary for EPT is not expressed in Prop1-cre; b-cat GOF/+ mutant embryos, which prevents the morphological formation of an anterior lobe.
The production of the b-catenin GOF protein in pituitary progenitors prevents the differentiation of hormone cell types. We were unable to detect individual hormones or the lineage-specific markers POU1F1, TBX19, and SF1 in Prop1-cre;b-cat GOF/+ mutant embryos. Additionally, the large epithelial cell clusters did not express the pituitary progenitor transcription factors SOX2, LHX3, and PROP1, and they had a decrease in SOX9 expression. This result demonstrates that persistent b-catenin GOF protein in pituitary progenitors shifts these cells away from a pituitary identity. ACP tumors do not produce pituitary hormones, but they can become calcified and produce enamel proteins characteristic of teeth (77) . ACPs could represent a reversion of pituitary progenitors to an earlier, oral ectodermal fate. CK8 and CK18 were used previously to identify Hesx1-cre; b-cat GOF/+ tumors as having an epithelial phenotype, consistent with oral ectoderm (20) . We used an antibody that recognizes both CK8 and CK18 to characterize normal control and Prop1-cre;b-cat GOF/+ embryonic pituitaries. CK8/CK18 are expressed throughout the intermediate and anterior lobes of normal control embryos, demonstrating that this epithelial marker is part of a normal embryonic pituitary identity. In Prop1-cre; b-cat GOF/+ mutant pituitaries, the regions with high b-catenin expression did not express CK8/CK18, consistent with a shift of these cells away from a pituitary identity. The oral ectoderm expresses SHH prior to Rathke's pouch invagination, which is then inhibited in the pituitary progenitors as Rathke's pouch begins to form (78) . The large cell clusters of high b-catenin expression also express SHH, consistent with an early oral ectoderm identity. Further confirmation of the oral ectoderm identity of the regions with high b-catenin expression will require identification of markers that can discriminate between embryonic oral ectoderm and pituitary progenitors.
ACP tumors have a low mitotic index (79) . We used Ki67 and CCND2 as proliferative markers in the Prop1-cre;b-cat GOF/+ mutant pituitaries. Ki67 is primarily restricted to the epithelial regions outside the high b-catenin cell clusters, demonstrating that cells in high b-catenin cell clusters are not actively cycling. CCND2 is also expressed in actively cycling cells and is a target of canonical WNT signaling (80) . In large, high b-catenin cell clusters, CCND2 expression is significantly reduced, confirming that these epithelial regions are not actively cycling. The decreased expression of CCND2 in the large, high b-catenin cell clusters is contrary to the expected stimulation of CCND2 by canonical WNT signaling. However, in the small, high b-catenin cell clusters CCND2 is expressed at higher levels, consistent with its role as a canonical WNT signaling target. These contextdependent results indicate that the use of CCND2 as a potential readout of canonical WNT signaling in ACP should be used with caution.
An intriguing observation from our study is that in normal control embryos, transcription from the b-catenin locus is reduced in the cells that undergo an EPT, whereas b-catenin protein is still present at the cell membranes. Increased levels of b-catenin generated from the gain-of-function allele both inhibit EPT and shift pituitary progenitors away from a pituitary identity. These results suggest that the amount b-catenin protein in pituitary progenitors must be tightly regulated to ensure proper formation of the pituitary anterior lobe. Decreased transcription during pituitary EPT may provide a regulatory mechanism for ensuring the appropriate levels of b-catenin protein to provide junctional stability and transcriptional regulation of the POU1F1 lineage, without preventing EPT or promoting an oral ectoderm identity.
The Hesx1-cre;b-cat GOF and Sox2 creERT2 ;b-cat GOF mouse models combined with molecular characterization of human ACP have determined that congenital and adult-onset ACP are caused by gain-of-function mutations in b-catenin in pituitary progenitors during embryogenesis or adult pituitary stem cells, respectively (81) . Intriguingly, these ACP tumors are formed in a paracrine manner where a cell cluster with a b-catenin activating mutation signals to adjacent cells, which then proliferate and expand to form the mass of the tumor (62) . The generation of ACP relies on the interaction of a cell cluster with high b-catenin expression surrounded by normal pituitary anterior lobe cells, which can respond to the paracrine signals. Our mouse model, Prop1-cre;b-cat GOF/+ , differs from these other mouse models in that a pituitary anterior lobe is not generated and the dysmorphic tissue consists of periluminal epithelium with high b-catenin expression. The earlier onset of the Hesx1-cre vs the Prop1-cre likely causes the differing phenotypes. Perhaps early pituitary progenitors, which express Hesx1, can inhibit transcription from the b-catenin locus, which prevents the accumulation of the b-catenin GOF protein in some cells and allows for anterior lobe formation. Children with b-catenin activating mutations that mimic the onset of the Prop1-cre; b-cat GOF would present with a complete pituitary hormone deficiency at birth. The morphology of the pituitary gland would likely resemble the initially enlarged pituitary gland of PROP1 2/2 CPHD patients, where the pituitary progenitors fail to perform the EPT necessary for anterior lobe formation (74, 82) .
